Clinical Trial Search

Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment.(Motor Scores) — 0; 3; 0; 0 Participants

Primary: Change of Pain Measured by VAS — 5.8; 2.2; 0.6; 1.2 pain intensity

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment (Motor Scores). — 10; 5; 0; 1 participants

Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05

Primary: Number of Participants With Bacterial Vaginosis Recurrence — 8 Participants

Primary: Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events — 1; 0 Participants

Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001

Primary: Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2 — 35; 35 Subjects

Primary: Number of CMV Seropositive Subjects With Appearance or Increase of Anti-CMV Tegument Protein IgG Antibodies in Serum. — 5; 2 Participants

Primary: Survival With no or Mild Neuropsychological Impairment at 12 Months After Initiation of Study Medication as Measured by the Mattis Dementia Rating Scale (MDRS) — 28; 34…

Primary: Sensitivity of Detection of HSV DNA by GeneXpert PCR From Specimens Obtained From the Genital Tract of Non-pregnant Women in STI Clinics, as Compared With HSV Culture…

Primary: Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation — -0.53; 0.03 log10 copies/mL

Primary: Number of Participants With Preterm Delivery — 100; 83; 247; 5407 Participants

Primary: Change in Standardized Uptake Value Ratio (SUVR) of (18F-Florbetapir PET) From Week 0 to Week 52. — 0.07; 0.08 Standardized Uptake Value Ratio

Primary: Herpes Simplex Virus Type 2 Recurrence — 0; 0 Recurrence

Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)

Primary: Area Under the Curve Following Administration of Oral Valacyclovir Suspension 20 mg/kg Every 8 Hours — 28.8 mgxh/l

Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716

Primary: Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline — 2; 3 participants

Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…

Primary: Percent Change in Overall Viral Shedding Rate From Baseline (Week -7 to 0) to Post-treatment Period (Weeks 6 to 13) — 13.53 percentage change

Primary: Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample — 6.49; 6.46; 6.07; 6.02 VZV genome copies per sample

Primary: Pharmacokinetics of Single Dose - Tmax — 1.00; 4; 1.02 hours

Primary: Time to Healing of Genital Lesions — 5.1; 6.0 Days

Primary: Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis) — 95; 110 participants — p=<0.05

Primary: Serious Adverse Device Effects — 0 Percentage SADE's

Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants

Primary: Alzheimer's Disease Assessment Scale - Cognition (ADAS-COG11, Modified Version) Score — 20.6; 19.2; 30.2; 25.3 score on a scale — p=<0.05

Primary: Investigator Assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 5.38; 4.79 Days — p=0.4161